About this trial
In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).
This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM.
The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group
Eligibility criteria
Qualifiers
Age over 18 years
BMI equal to or greater than 27.5 kg/m2
T2DM duration ≤ 10 years
Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication
Disqualifiers
Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy)
History of previous metabolic surgery for T2DM
History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery
Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders
Trial design
Treatments tested in this trial
- Duodenojejunal bypass
- Sleeve gastrectomy
Treatment groups
Sponsors and collaborators
Seoul National University Bundang Hospital
Lead sponsor
Ajou University School of Medicine
Collaborator
The Catholic University of Korea
Collaborator
The Catholic University of Korea Eunpyeong St. Mary's Hospital
Collaborator
Ewha Womans University Seoul Hospital
Collaborator
Seoul Metropolitan Boramae Hospital
Collaborator
Soonchunhyang University Hospital
Collaborator
Korea University
Collaborator